Study of Drug Interactions in Renal Cancer Cell Lines
Author Information
Author(s): Kaye J. Williams, Adam V. Patterson, Brian A. Telfer, Rachel L. Cowen, Mohammed Jaffar, Ian J. Stratford
Primary Institution: School of Pharmacy and Pharmaceutical Sciences, University of Manchester
Hypothesis
SN-38 and 5-FU may act synergistically in renal cancers, and that sequence is critical in this interaction.
Conclusion
The sequence of drug administration is crucial for achieving synergy between SN-38 and 5-FU in renal cancer cell lines.
Supporting Evidence
- In RCC39 and RCC42, the sequence of SN-38 followed by 5-FU showed marked synergy.
- 5-FU exposure resulted in increases in TS protein in RCC39 and RCC42.
- Synergy was not found with RCC45.
Takeaway
Using two cancer drugs in a specific order can make them work better together to kill cancer cells.
Methodology
Cells were treated with different sequences of SN-38 and 5-FU, and their viability was measured.
Limitations
The study was limited to three specific renal cancer cell lines.
Participant Demographics
RCC39, RCC42, RCC45 renal cancer cell lines.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website